Why the study?
To fill the knowledge gap regarding the structure-activity relationships, advancements, and trends of nucleobase-containing drugs as antiviral therapeutics from 2015 to the present.
This review highlights the structural modifications and therapeutic potential of nucleobase-containing drugs against a diverse range of viral diseases.
Novel NCDs may broaden antiviral strategies; leaves open clinical adoption pending prospective trials.
Nucleobases serve as essential molecular frameworks present in both natural and synthetic compounds that exhibit notable antiviral activity. Through molecular modifications, novel nucleobase-containing drugs (NCDs) have been developed, exhibiting enhanced antiviral activity against a wide range of viruses, including the recently emerged SARS‑CoV‑2. This article provides a detailed examination of the significant advancements in NCDs from 2015 till current, encompassing various aspects concerning their mechanisms of action, pharmacology and antiviral properties. Additionally, the article discusses antiviral prodrugs relevant to the scope of this review. It fills in the knowledge gap by examining the structure-activity relationship and trend of NCDs as therapeutics against a diverse range of viral diseases, either as approved drugs, clinical candidates or as early-stage development prospects. Moreover, the article highlights on the status of this field of study and addresses the prevailing limitations encountered.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: